Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03656809 · ClinicalTrials.gov registry record
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
A clinical trial of Ovarian Cancer, sponsored by NYU Langone Health.
- Completed
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT03656809: Completed study of Ovarian Cancer, sponsored by NYU Langone Health.
NCT03656809 is a study of Ovarian Cancer that has completed, run by NYU Langone Health. The registered enrollment target is 125 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03656809, a study of Ovarian Cancer, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the feasibility of routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer.
Conditions Studied
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2020-01-29 |
What the finished NCT03656809 record still lists
NCT03656809 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03656809 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03656809 about?
NCT03656809 is a clinical study titled "Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer". The purpose of this study is to determine the feasibility of routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer.
What is the current status of trial NCT03656809?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2015-10-15. Estimated completion is 2020-01-29.
What conditions does trial NCT03656809 study?
This clinical trial studies the following conditions: Ovarian Cancer.
Who is sponsoring clinical trial NCT03656809?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03656809 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03656809's enrollment target sits among peer trials
125 131st of 322 higher than 192 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI